NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) Valuation Check After Swing To Profit On Strong 2025 Earnings
What Alnylam’s latest earnings tell you
Alnylam Pharmaceuticals (ALNY) just reported Q4 and full year 2025 results that moved from losses to profits, with revenue and earnings shifting sharply higher compared with the previous year.
For Q4 2025, revenue came in at US$1,097.03 million versus US$593.17 million a year earlier, and net income was US$111.54 million after a net loss of US$83.76 million in the prior year period.
On a per share basis for the quarter, basic earnings from continuing...